High-Normal Serum Thyrotropin Levels Increased the Risk of Non-Alcoholic Fatty Liver Disease in Euthyroid Subjects with Type 2 Diabetes

Ying Tan¹,*
Xixiang Tang¹,²,*
Panwei Mu¹
Yi Yang¹
Mei Li¹,²
Yuanpeng Nie¹
Haicheng Li¹
Yanhua Zhu²
Yanming Chen¹

¹Department of Endocrinology & Metabolism, The Third Affiliated Hospital of Sun Yat-sen University, Guangdong Provincial Key Laboratory of Diabetology, Guangzhou, People’s Republic of China; ²VIP medical service center, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, People’s Republic of China

*These authors contributed equally to this work

Purpose: The aim of this study was to investigate the association between high-normal thyrotropin (TSH) levels and the prevalence of non-alcoholic fatty liver disease (NAFLD) in euthyroid patients with T2DM.

Methods: A total of 2289 euthyroid adults with T2DM were included in this cross-sectional study conducted at the Third Affiliated Hospital of Sun Yat-sen University from January 2016 to December 2018. NAFLD was diagnosed by abdominal ultrasound. Thyroid function parameters, including the levels of TSH, free triiodothyronine (FT3) and free thyroxine (FT4), were analyzed. The patients were stratified by quartiles (Q1–4) of TSH levels. Multivariate logistic regression models were used to evaluate the association between the quartiles of TSH levels and the risk of NAFLD in euthyroid adults with T2DM.

Results: There were 940 (41.1%) euthyroid adults with T2DM who were diagnosed with NAFLD. The subjects were divided according to the thyroid function parameter quartiles. The prevalence of NAFLD increased with increasing TSH level quartiles (Q1 to Q4: 34.8%, 37.5%, 44.9% and 47.0%, P<0.01) but not with increasing FT3 or FT4 level quartiles. In the multivariate logistic regression model, compared with the lowest TSH level quartile (Q1), the highest TSH level quartile (Q4) (OR=1.610, 95% CI=1.131–2.289, P=0.008) was independently associated with an increased risk of NAFLD in euthyroid adults with T2DM after adjusting for multiple confounders. After additional stratification by the level of glycosylated haemoglobin (HbA1c) and body mass index (BMI), the highest TSH level quartile was still independently associated with an increased risk of NAFLD in euthyroid patients with T2DM who had an HbA1c level≥7% or a BMI<28 kg/m².

Conclusion: High-normal serum TSH levels are significantly associated with the presence of NAFLD in T2DM patients with euthyroid function, which provide novel insight for treating NAFLD.

Keywords: non-alcoholic fatty liver disease, type 2 diabetes, thyroid hormone

Introduction
Non-alcoholic fatty liver disease (NAFLD) is emerging as a public health issue worldwide and encompasses a wide spectrum of pathologic liver conditions ranging from simple steatosis to steatohepatitis and cirrhosis.¹,² NAFLD and type 2 diabetes mellitus (T2DM) are common conditions that regularly coexist. The overall prevalence of NAFLD among patients with T2DM is 55.5%.³ These two diseases could act synergistically and drive many adverse outcomes, including the complications of diabetes, cardiovascular disease, liver-related mortality and all-cause...
mortality.\textsuperscript{4,5} Thus, a better understanding of the risk factors for the incidence of NAFLD in patients with T2DM is needed.

It is well known that thyroid hormone regulates favorable metabolic processes, including thermogenesis, lipid metabolism, and carbohydrate metabolism.\textsuperscript{6} Thyroid hormone is involved in lipid metabolism in hepatocytes.\textsuperscript{7} Abundant studies have shown that both hypothyroidism and subclinical hypothyroidism are associated with NAFLD.\textsuperscript{8,9} Several studies have demonstrated that thyroid hormone is associated with the risk of NAFLD in euthyroid subjects.\textsuperscript{10-12} However, few data exist regarding the association between serum thyroid hormone levels in the normal range and NAFLD in patients with T2DM.

Therefore, this study aimed to investigate the association between normal thyroid function and the prevalence of NAFLD in euthyroid adults with T2DM.

Methods

Study Design and Participants

This retrospective cross-sectional study was conducted in our hospital between January 2016 and December 2018. T2DM patients who were admitted to the hospital for glycemic control were enrolled. T2DM was diagnosed according to the 1999 criteria of the World Health Organization (WHO).\textsuperscript{13} Subjects who had pairs of thyroid function tests and hepatic ultrasonography measurements were included in the study. Only euthyroid subjects participated in the present study. In this study, euthyroidism was defined as a TSH level between 0.35 and 4.94 μIU/mL, FT4 level between 9.01 and 19.05 pmol/L and FT3 level between 2.63 and 5.70 pmol/L according to the normal reference value of thyroid function tests in our hospital. The diagnosis of NAFLD was made based on the guidelines for prevention and treatment of NAFLD.\textsuperscript{14}

The exclusion criteria were as follows: (1) type 1 diabetes, latent immune diabetes of adults, and specific types of diabetes; (2) history of thyroid diseases, abnormal thyroid hormone levels, treatment history with anti-thyroid drugs or other drugs that could potentially influence thyroid function (eg, amiodarone, lithium, corticosteroids, etc.); (3) subjects reporting significant alcohol consumption (>30 g/day for men and >20 g/day for women); and (5) subjects infected with hepatitis B or hepatitis C virus, known to have pre-existing chronic liver disease (eg, Wilson's disease, haemochromatosis, autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, drug-induced liver disease). Ethics approval was obtained from the Third Affiliated Hospital of Sun Yat-sen University Network Ethics Committee. Informed consent was obtained from all participants.

Data Collection

Demographic and clinical information, including age, sex, height, body weight, blood pressure, lifestyle factors (smoking status and alcohol consumption), comorbidities, duration of diabetes, diabetes therapy (antihyperglycemic agents, insulin injection) and medications, was collected. Concentrations of biochemical parameters, including fasting plasma glucose (FPG), blood urea nitrogen (BUN), creatinine, uric acid, triglycerides, total cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) plasma aspartate transaminase (AST), alanine transaminase (ALT), gamma glutamyltransferase (GGT), alkaline phosphatase (ALP), total bilirubin (TBIL) and indirect bilirubin (IBIL), were measured by a HITACHI 7180 automatic analyzer. HbA1c was measured by the D-10 haemoglobin testing program (Bio-Rad) with high-performance liquid chromatography (HPLC). Thyroid function tests, including free thyroxine (FT4), free triiodothyronine (FT3) and thyroid-stimulating hormone (TSH), were measured by chemiluminescent immunoassays on an Abbott i4000 automatic analyzer. The homoeostasis model assessment of insulin resistance (HOMA-IR) was calculated according to the formula fasting insulin*FPG/22.5.\textsuperscript{15}

Diagnosis of NAFLD

NAFLD is defined as the presence of steatosis in the liver when secondary causes of fatty infiltration in the liver have been excluded.\textsuperscript{14} Hepatic steatosis was diagnosed using ultrasound scans according to the guidelines for prevention and treatment of non-alcoholic fatty liver disease.\textsuperscript{14} The ultrasound examinations were performed with GE-LOGIQ E9 ultrasound machines by experienced ultrasonographic physicians who were blinded to the study.

Statistical Analysis

Database management and statistical analysis were performed by using SPSS 22.0 for Windows (SPSS Inc, Chicago, IL, USA). Descriptive statistics are presented as the mean ± standard deviation for continuous variables or as numbers and percentages for categorical variables. All patients were grouped into quartiles of TSH (Q1 = the first quartile; Q2 =
the second quartile; Q3 = the third quartile; Q4 = the fourth quartile). Continuous variables were compared by analysis of variance (ANOVA), while categorical variables were compared using the Pearson chi square test. Multivariate logistic regression analysis was performed to evaluate the effect of TSH levels on the risk of NAFLD in T2DM patients. To further assess whether glycemic status and obesity status confounded the relationship between TSH and the risk of NAFLD, subgroup analyses were performed based on HbA1c levels (<7.0% and ≥ 7.0%) and BMI (<28 and ≥ 28 kg/m²). A 2-tailed P value <0.05 was considered indicative of statistical significance.

**Results**

From January 2016 to December 2018, 6109 patients with T2DM were enrolled in the study. A total of 2734 patients who did not finish thyroid function testing or hepatic ultrasonography measurements were excluded. Another 1086 patients with abnormal thyroid function were also excluded. Finally, 2289 patients (1247 men and 1042 women; mean age, 55.8 ± 14.4 years) were included in the analysis (Figure 1). The median diabetes duration of the patients was 6 (2, 11) years, with a mean HbA1c level of 9.04 ± 2.52%. The mean FPG was 10.15 ± 6.45 mmol/L.

A total of 940 participants with T2DM were diagnosed with NAFLD, and the total prevalence of NAFLD in subjects with T2DM was 41.1%. As shown in Supplemental Table 1, patients with T2DM and NAFLD showed an elevated level of TSH, BUN, UA, TC, TG, HbA1c, BMI, SDP and DBP, with a lower diabetic duration, HDL-C level (all P<0.05). There were also significant differences in proportion of insulin injection, sulfonylureas, metformin, thiazolidinediones, GLP-1 receptor agonists, SGLT-2 inhibitors, statin and comorbidity of hyperlipidaemia between the type 2 diabetic patients with and without NAFLD (all P<0.05).

Then as shown in Figure 2, the prevalence of NAFLD had a positive trend with increasing quartile levels of TSH (34.8%, 37.5%, 44.9% and 47.0%, Q1 to Q4, respectively, P<0.05) but not with FT3 or FT4 quartile levels. Therefore, we divided the participants according to the quartiles of TSH level. Table 1 shows the clinical characteristics of the subjects grouped according to the quartiles of TSH levels. The concentrations of TSH were <0.96 mIU/L in Q1 subjects, 0.96–1.44 mIU/L in Q2 subjects, 1.44–2.13 mIU/L in Q3 subjects, and >2.13 mIU/L in Q4 subjects. Age, diabetes duration, proportion of insulin injection, metformin intake, comorbidity of hyperlipidaemia and hypertension, and levels of ALT, TBIL, Cr, BUN, TG, FPG, HbA1c, and FT3 varied within groups (P < 0.05). No significant differences in the other parameters were observed among subjects with different TSH quartiles.

**Univariate and Multivariate Logistic Regression Analysis**

In the univariable model, the TSH levels in Q3 and Q4 showed significant associations with the risk of NAFLD (P < 0.0001) (Supplemental Table 2). When further adjusting...
for age and sex (model 1), the TSH levels of participants in Q3 and Q4 were still independently related to the risk of NAFLD ($P < 0.05$). After further adjustment for BMI, diabetes duration, levels of HDL-C, LDL-C, TGs, HbA1c, FT3, and FT4, smoking status, alcohol intake, insulin injection and metformin use, patients in Q4 remained at a higher risk of NAFLD than patients in Q1 ($P < 0.05$) (model 2) (Figure 3).

### Subgroup Analysis

As shown in Supplemental Table 3, TSH levels of the patients in the Q3 and Q4 quartiles were significantly associated with the risk of NAFLD regardless of the HbA1c level and in the BMI <28 kg/m$^2$ subgroup ($P<0.05$) in the univariable model or after further adjustment for age and sex (model 1). In the multivariate analysis adjusted for age, sex, BMI, diabetes duration, levels of HDL-C, LDL-C, TGs, HbA1c, FT3, and FT4, smoking status, alcohol intake, insulin injection and metformin use, TSH levels in Q4 continued to be a strong determinant of the risk of NAFLD in the HbA1c $\geq 7.0\%$ or BMI <28 kg/m$^2$ subgroup (all $P < 0.05$) (Figure 4).

### Discussion

This cross-sectional study revealed that high-normal TSH levels were associated with an increased risk of NAFLD in euthyroid adults with T2DM, particularly for subjects with an HbA1c level $\geq 7.0\%$ or a BMI <28 kg/m$^2$. This result suggested that a high-normal TSH level was an independent risk factor for NAFLD in T2DM patients.

NAFLD is common among individuals with T2DM. The prevalence of NAFLD in T2DM patients differed by sex and the presence of obesity, hypertension, dyslipidemia, coronary heart disease, and chronic kidney disease. Thyroid hormones have important roles in regulating energy balance and metabolism. Some studies have explored whether thyroid hormone disorder is a risk factor for the development of NAFLD and T2DM. Several studies have shown that a low-normal thyroid hormone level is associated with high fasting glucose levels and a high HbA1c level. Furthermore, higher-normal serum TSH levels were associated with the incidence of T2DM. Regarding the relationship between TSH and NAFLD, many studies have proven that subclinical hypothyroidism is a risk factor for NAFLD, and an increase in TSH levels is positively correlated with the incidence of NAFLD. Notably, high TSH levels have been reported to be associated with the severity of hepatic steatosis. In addition, in euthyroid subjects, several studies have demonstrated that high TSH levels are associated with the risk of NAFLD. Recently, a study with small participant sample showed that NAFLD in euthyroid T2DM patients may be associated with thyroid hormone resistance-like manifestation. Consistently, our study confirmed that a higher-normal TSH level was associated with an increased risk of NAFLD in euthyroid subjects with T2DM.

It is likely that TSH plays an important role in the incidence of NAFLD in patients with T2DM. Of note, the present study revealed that serum TSH levels in the upper normal range are associated with the incidence of NAFLD.
### Table 1 Clinical Characteristics of the Participants According to Quartiles of Serum TSH Levels

| Variables (% or Mean ± SD) | Total     | Quartile of TSH | P-value |
|----------------------------|-----------|-----------------|---------|
| n                          | 2289      | 572             | 573     | 572     | 572     |         |
| TSH, mIU/L                 | 1.65 ± 0.91 | 0.71 ± 0.16     | 1.20 ± 0.14 | 1.76 ± 0.20 | 2.93 ± 0.68 | <0.001 |
| Male, n (%)                | 1247 (54.5) | 351 (61.4)      | 326 (56.9) | 307 (53.7) | 263 (46.0) | <0.001 |
| Age, years                 | 55.8 ± 14.4 | 55.1 ± 13.8     | 54.5 ± 14.8 | 56.2 ± 14.7 | 57.6 ± 14.3 | 0.002  |
| Waist circumference, cm    | 89.4 ± 10.5 | 89.23 ± 10.23   | 88.46 ± 10.77 | 90.14 ± 10.49 | 89.82 ± 10.28 | 0.196  |
| BMI, kg/m²                 | 24.69 ± 8.93 | 24.16 ± 3.82   | 24.53 ± 10.12 | 25.18 ± 9.52 | 24.87 ± 10.49 | 0.319  |
| SBP, mmHg                  | 131.3 ± 20.4 | 129.9 ± 19.9   | 130.4 ± 19.3 | 132.4 ± 21.6 | 132.4 ± 20.7 | 0.131  |
| DBP, mmHg                  | 79.3 ± 11.7 | 79.5 ± 12.2     | 79.7 ± 11.1 | 79.9 ± 12.0 | 78.1 ± 11.4 | 0.082  |
| **Blood biochemical indices** |           |                 |         |         |         |         |
| ALT, U/l                   | 28.6 ± 5.1  | 30.9 ± 8.7      | 26.5 ± 5.5  | 24.7 ± 8.4  | 28.6 ± 5.0  | 0.012  |
| AST, U/l                   | 24.3 ± 6.1  | 25.3 ± 9.2      | 22.4 ± 4.1  | 26.7 ± 3.7  | 22.7 ± 5.6  | 0.054  |
| TBIL, nmol/l               | 11.46 ± 5.64 | 11.89 ± 6.40   | 11.66 ± 5.41 | 11.38 ± 5.14 | 10.90 ± 5.51 | 0.026  |
| IBIL, nmol/l               | 7.50 ± 3.63 | 7.68 ± 3.87     | 7.67 ± 3.63 | 7.47 ± 3.47 | 7.18 ± 3.52 | 0.088  |
| GGT, nmol/l                | 25 (17, 38) | 23 (16, 37)     | 25 (18, 37) | 26 (18, 40) | 24 (16, 37.5) | 0.506  |
| ALP, nmol/l                | 77.24 ± 37.22 | 78.37 ± 35.68 | 77.18 ± 37.75 | 76.28 ± 33.23 | 77.15 ± 41.76 | 0.836  |
| Cr, umol/l                 | 81.10 ± 61.41 | 76.52 ± 45.43 | 75.42 ± 39.51 | 83.67 ± 67.29 | 88.86 ± 82.80 | <0.001 |
| BUN, umol/l                | 5.93 ± 2.74  | 5.79 ± 2.65     | 5.63 ± 2.02 | 6.05 ± 3.02 | 6.25 ± 3.09 | 0.001  |
| UA, umol/l                 | 366.95 ± 110.59 | 358.88 ± 110.95 | 363.67 ± 103.27 | 375.77 ± 111.51 | 369.59 ± 115.81 | 0.065  |
| TC, mmol/l                 | 4.79 ± 1.32  | 4.74 ± 1.36     | 4.78 ± 1.17 | 4.83 ± 1.23 | 4.82 ± 1.48 | 0.619  |
| TG, mmol/l                 | 1.34 (0.94, 1.99) | 1.20 (0.86, 1.80) | 1.35 (0.93, 1.96) | 1.41 (0.99, 2.07) | 1.41 (0.96, 2.11) | 0.049  |
| HDL-C, mmol/l              | 1.11 ± 0.32  | 1.10 ± 0.33     | 1.11 ± 0.32 | 1.11 ± 0.31 | 1.12 ± 0.32 | 0.827  |
| LDL-C, mmol/l              | 2.94 ± 0.99  | 2.94 ± 0.98     | 2.98 ± 0.96 | 2.98 ± 0.96 | 2.86 ± 1.05 | 0.168  |
| **Lifestyles, n (%)**       |           |                 |         |         |         |         |
| Smoking, n (%)             | 586 (25.6) | 178 (31.1)      | 170 (29.7) | 132 (23.1) | 106 (18.5) | <0.001 |
| Alcohol, n (%)             | 347 (15.2) | 89 (15.6)       | 100 (17.5) | 74 (12.9)  | 84 (14.7)  | 0.185  |
| **Diabetes-related variables** |           |                 |         |         |         |         |
| Diabetes duration, years   | 6 (2.11)  | 6 (1.1)         | 6 (2.1)  | 6 (2.11)  | 8 (2.14)  | <0.001 |
| HbA1c, %                   | 10.15 ± 6.45 | 11.42 ± 7.36   | 10.03 ± 6.40 | 9.81 ± 6.15 | 9.35 ± 5.58 | <0.001 |
| HOMA-IR                    | 9.04 ± 2.52 | 9.67 ± 2.70     | 9.09 ± 2.51 | 8.88 ± 2.41 | 8.54 ± 2.30 | <0.001 |
| FPG, mmol/L                | 6.01 ± 1.774 | 5.98 ± 12.84   | 5.30 ± 8.23 | 7.47 ± 13.80 | 5.32 ± 6.18 | 0.405  |
| HbA1c, %                   | 34.32 ± 0.67 | 42.5 ± 0.67     | 43.7 ± 0.66 | 43.4 ± 0.66 | 43.4 ± 0.68 | 0.018  |
| DPP-4 Inhibitors           | 4.32 ± 0.67 | 42.5 ± 0.67     | 43.7 ± 0.66 | 43.4 ± 0.66 | 43.4 ± 0.68 | 0.018  |
| GLP-1 receptor agonists    | 18 (2.4)    | 18 (2.4)        | 18 (2.4)  | 18 (2.4)  | 18 (2.4)  | 0.405  |
| SGLT2 Inhibitors           | 37 (1.6)    | 37 (1.6)        | 37 (1.6)  | 37 (1.6)  | 37 (1.6)  | 0.405  |
| Statin                     | 105 (43.9)  | 105 (43.9)      | 105 (43.9) | 105 (43.9) | 105 (43.9) | 0.405  |
| Anti-platelet              | 105 (43.9)  | 105 (43.9)      | 105 (43.9) | 105 (43.9) | 105 (43.9) | 0.405  |

(Continued)
in T2DM patients with HbA1c≥7% but not in patients with HbA1c<7%. A longitudinal study demonstrated that an increase in TSH levels was related to an increase in HbA1c and FPG levels and that there was an increased risk of NAFLD with increasing levels of HbA1c independent of obesity. In addition, a high-normal TSH level is related to increased insulin resistance and increased glycemic variability and may contribute to glycemic disorders in diabetes. Therefore, a high-normal serum TSH level remains a significant additional risk factor for the increased risk of NAFLD in type 2 diabetic patients with poor glycemic control. In patients with T2DM without evidence of thyroid disease, a higher serum TSH level was closely associated with central obesity and hyperlipidaemia, which are closely related to the pathogenesis of NAFLD. Interestingly, the present study found that a high-normal TSH level is a risk factor for the incidence of NAFLD in non-obese patients with T2DM but not in obese patients. The major contributing factors to lean NAFLD have been reported and include insulin resistance, hypertriglyceridaemia, and hyperandrogenaemia, which may be associated with TSH levels.

The mechanism for the association between a high-normal serum TSH level and an increased risk of NAFLD remains unclear. However, several possible mechanisms are available to explain the link. The relationship between NAFLD and T2DM has been well established, which could be explained by insulin resistance and compensatory hyperinsulinaemia leading to abnormal lipid metabolism and hepatic triglyceride accumulation in NAFLD. Hypothyroidism has been associated with insulin resistance, obesity, and even metabolic syndrome, which play an important role in the development of NAFLD. Moreover, in euthyroid individuals without T2DM or with T2DM, increased TSH-normal levels were associated with visceral obesity, increased triglyceride concentrations and reduced insulin sensitivity, which may promote the occurrence of NAFLD. In addition, NAFLD patients have displayed increased tumor necrosis factor alpha (TNF-a), elevated leptin levels, and decreased adiponectin levels compared to healthy controls. Alterations in serum levels of

Table 1 (Continued).

| Variables (% or Mean ± SD) | Total | Quartile of TSH | P-value |
|---------------------------|-------|----------------|---------|
|                           |       | 1              | 2       | 3       | 4       |
| Comorbidity, n (%)        |       |                |         |         |         |
| Cardiovascular disease    | 194 (8.5) | 50 (8.7) | 45 (7.9) | 47 (8.2) | 52 (9.1) | 0.881 |
| Hyperlipidemia            | 115 (5.0) | 23 (4.0) | 18 (3.1) | 35 (6.1) | 39 (6.8) | 0.013 |
| Hypertension              | 799 (34.9) | 185 (32.3) | 180 (31.4) | 205 (35.8) | 229 (40.0) | 0.009 |

Note: Data are mean ± SD, median (25th to 75th percentile) or n (%).

Abbreviations: TSH, thyroid-stimulating hormone; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; FPG, fasting plasma glucose; HOMA-IR, homeostatic model assessment of insulin resistance; FT3, free triiodothyronine; FT4, free thyroxine; ALT, alanine aminotransferase; AST, aspartate aminotransferase; TBIL, total bilirubin; IBIL, indirect bilirubin; GGT, glutamyl transpeptidase; ALP, alkaline phosphatase; Cr, plasma creatinine; BUN, blood urea nitrogen; UA, uric acid; TC, total cholesterol; TG, triglycerides; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol.

Figure 3 Logistic regression analysis regarding the effects of TSH level on the risk of NAFLD (Model 2).
cytokines and adipokines will affect liver inflammation and increase lipogenesis.\(^{34}\) The level of TSH could affect the level of adipokines, thus contributing to the development of NAFLD.\(^{36,37}\)

Our study has several limitations. The diagnosis of hepatic steatosis in our study was confirmed using ultrasonography but not liver biopsy, which is the gold standard for the diagnosis of NAFLD.\(^{14,38}\) Nevertheless, conventional ultrasonography, a non-invasive assessment, is the most commonly used imaging method for the diagnosis of hepatic steatosis because it is widely available, well established, well tolerated, and inexpensive. European guidelines for the management of NAFLD recommend using ultrasonography as first-choice imaging in adults at risk for NAFLD.\(^ {39}\) Second, this is a cross-sectional study; therefore, this study could not reflect the causal effect of TSH levels on NAFLD in diabetic patients. Third, anti-thyroid peroxidase and anti-thyroglobulin autoantibodies were not considered in the present study. Thus, the possible influence of impending thyroid autoimmunity on the association between NAFLD and thyroid function cannot be ruled out.

**Conclusions**

In summary, our study demonstrated that a high-normal serum TSH level be significantly associated with the presence of NAFLD in type 2 diabetic patients with normal thyroid function. Thyroid hormone levels may need to be considered in evaluating the risk of NAFLD in T2DM and providing novel insight for treating NAFLD. More studies are needed to confirm the mechanism of TSH and NAFLD in diabetic patients with normal thyroid function.

**Statement of Ethics**

We promised that the data of the participants were anonymized or maintained with confidentiality and confirmed that the guidelines outlined in the Declaration of Helsinki were followed.

**Funding**

This study was funded by National Key R&D Program of China (2017YFA0105803), the National Natural Science Foundation of China (81770826, 82000278), the 5010 Clinical Research Projects of Sun Yat-sen University (2015015), the Key Area R&D Program of Guangdong Province (2019B020227003), the Science and Technology Plan Project of Guangzhou City (202007040003), the Guangdong Basic and Applied Basic Research Foundation (2020A1515010599), and the fostering special funding projects of the National Natural Science Foundation of China in the third affiliated hospital of SYSU (2020GZRPYQN04).

**Disclosure**

The authors report no conflicts of interest in this work.
Ludwig U, Holzner D, Denzer C, et al. Subclinical and clinical hypothyr...
38. Wong VW, Chan W-K, Chitturi S, et al. Asia-pacific working party on non-alcoholic fatty liver disease guidelines 2017-Part 1: definition, risk factors and assessment. J Gastroenterol Hepatol. 2018;33(1):70–85. doi:10.1111/jgh.13857

39. EASL E. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388–1402. doi:10.1016/j.jhep.2015.11.004